First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia

Iadademstat is a novel, highly potent, and selective inhibitor of LSD1 (KDM1A), with preclinical in vitro and in vivo antileukemic activity. This study aimed to determine safety and tolerability of iadademstat as monotherapy in patients with relapsed/refractory acute myeloid leukemia (R/R AML). METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Salamero, Olga, Montesinos, Pau, Willekens, Christophe, Pérez-Simón, José Antonio, Pigneux, Arnaud, Récher, Christian, Popat, Rakesh, Carpio, Cecilia, Molinero, César, Mascaró, Cristina, Vila, Joaquim, Arévalo, M. Isabel, Maes, Tamara, Buesa, Carlos, Bosch, Francesc, Somervaille, Tim C. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768337/
https://www.ncbi.nlm.nih.gov/pubmed/33052756
http://dx.doi.org/10.1200/JCO.19.03250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768337/
https://www.ncbi.nlm.nih.gov/pubmed/33052756
http://dx.doi.org/10.1200/JCO.19.03250

Ejemplares similares